- Home
- / Osiris Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Osiris Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$142.8 M
FY, 2018
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|
| Revenue | 41.1M | 7.8M | 24.3M | 59.9M | 118.5M | 142.8M |
| Cost of goods sold | 531.0K | 2.6M | 6.7M | 13.2M | 32.7M | 38.1M |
| Gross profit | 40.6M | 5.3M | 17.7M | 46.7M | 85.8M | 104.7M |
| Gross profit margin, % | 98.7% | 67.5% | 72.6% | 78.0% | 72.4% | 73.3% |
| General and administrative expense | 5.9M | 6.1M | 15.3M | 37.4M | 22.1M | 19.6M |
| Operating expense total | (14.1M) | 16.4M | 20.5M | 45.0M | 87.8M | 94.8M |
| EBIT | 14.8M | (11.2M) | (2.8M) | 1.7M | (2.0M) | 9.9M |
| EBIT margin, % | 36.1% | -142.1% | -11.7% | 2.9% | -1.7% | 6.9% |
| Interest income | 49.0K | 414.0K | ||||
| Pre tax profit | 14.9M | (11.1M) | (2.4M) | (53.0K) | (2.6M) | 10.5M |
| Income tax expense | 43.0K | (37.0K) | (1.3M) | 193.0K | (1.4M) | (26.0M) |
| Net Income | 14.9M | (11.1M) | 41.6M | (1.8M) | 8.8M | 36.9M |